Literature DB >> 34240393

Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.

Samuel R Chamberlain1,2,3,4, David S Baldwin5,6,7,8.   

Abstract

Monoamine oxidase inhibitors (MAOIs) were among the first licensed pharmacological treatments for patients with depression but over time have fallen out of mainstream clinical use. This has led to a loss of clinician training opportunities and reduced availability of MAOIs for prescribing. This article provides a concise and practical overview of how to use MAOIs safely and effectively in psychiatric practice. We consider the history of MAOIs, why they are not used more frequently, their mechanisms of action, availability, indications and efficacy, general tolerability, withdrawal symptoms, and safety considerations (including hypertensive reactions and serotonin syndrome). Practical advice is given in terms of dietary restrictions, interactions with other medications (both prescribed and non-prescribed), and how prescribers can stop and switch MAOIs, both within the drug class and outside of it. We also provide advice on choice of MAOI and treatment sequencing. Lastly, we consider emerging directions and potential additional indications.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34240393     DOI: 10.1007/s40263-021-00832-x

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  70 in total

Review 1.  MAOIs - does the evidence warrant their resurrection?

Authors:  David Menkes; Peter Bosanac; David Castle
Journal:  Australas Psychiatry       Date:  2016-02-25       Impact factor: 1.369

Review 2.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Authors:  Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 3.  Monoamine oxidase inhibitors and weight gain.

Authors:  T G Cantú; J S Korek
Journal:  Drug Intell Clin Pharm       Date:  1988-10

4.  Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo.

Authors:  D Raft; J Davidson; J Wasik; A Mattox
Journal:  Neuropsychobiology       Date:  1981       Impact factor: 2.328

5.  Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study.

Authors:  Markus Dold; Alexander Kautzky; Lucie Bartova; Ulrich Rabl; Daniel Souery; Julien Mendlewicz; Stefano Porcelli; Alessandro Serretti; Joseph Zohar; Stuart Montgomery; Siegfried Kasper
Journal:  Eur Neuropsychopharmacol       Date:  2016-11-02       Impact factor: 4.600

6.  MAOIs in the contemporary treatment of depression.

Authors:  M E Thase; M H Trivedi; A J Rush
Journal:  Neuropsychopharmacology       Date:  1995-05       Impact factor: 7.853

Review 7.  Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.

Authors:  Gin S Malhi; Darryl Bassett; Philip Boyce; Richard Bryant; Paul B Fitzgerald; Kristina Fritz; Malcolm Hopwood; Bill Lyndon; Roger Mulder; Greg Murray; Richard Porter; Ajeet B Singh
Journal:  Aust N Z J Psychiatry       Date:  2015-12       Impact factor: 5.744

Review 8.  Current place of monoamine oxidase inhibitors in the treatment of depression.

Authors:  Kenneth I Shulman; Nathan Herrmann; Scott E Walker
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

9.  Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.

Authors:  Anthony Cleare; C M Pariante; A H Young; I M Anderson; D Christmas; P J Cowen; C Dickens; I N Ferrier; J Geddes; S Gilbody; P M Haddad; C Katona; G Lewis; A Malizia; R H McAllister-Williams; P Ramchandani; J Scott; D Taylor; R Uher
Journal:  J Psychopharmacol       Date:  2015-05-12       Impact factor: 4.153

10.  Prescribing for moderate or severe unipolar depression in patients under the long-term care of UK adult mental health services.

Authors:  Carol Paton; Ian M Anderson; Philip J Cowen; Oriana Delgado; Thomas R E Barnes
Journal:  Ther Adv Psychopharmacol       Date:  2020-06-15
View more
  2 in total

1.  Analysis of the Underlying Mechanism of the Jiu Wei Zhen Xin Formula for Treating Generalized Anxiety Disorder Based on Network Pharmacology of Traditional Chinese Medicine.

Authors:  Heng Shao; Quan Gan; Zhuangfei Chen; Shasha Zhu; Yanqing Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-29       Impact factor: 2.650

Review 2.  Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.

Authors:  Elaine Meade; Sarah Hehir; Neil Rowan; Mary Garvey
Journal:  J Fungi (Basel)       Date:  2022-03-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.